Key Dates

Related Announcements

RFA-NS-23-012 - Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

NOT-NS-23-060 - Technical Assistance Webinars for RFA-NS-23-012 "Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Office of The Director, National Institutes of Health (OD)

Purpose

The purpose of this notice is to inform interested applicants of a change to the Key Dates for RFA-NS-23-012 “ Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)”. The new application due date for this Funding Opportunity Announcement (FOA) has been moved from March 23, 2023 to May 1, 2023. Changes to the FOA are shown below.

Currently Reads:

Part 1. Overview Information

Key Dates:

    Open Date (Earliest Submission Date): February 23, 2023     

    Letter of Intent Due Date: February 23, 2023

Expiration Date: March 24, 2023

Modified to Read: 

Part 1. Overview Information

Key Dates:

    Open Date (Earliest Submission Date): April 1, 2023    

    Letter of Intent Due Date: April 1, 2023

Expiration Date: May 2, 2023

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Amelie Gubitz, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Division of Neuroscience
Email: [email protected]